Neurochemistry and neuropharmacology of schizophrenia
著者
書誌事項
Neurochemistry and neuropharmacology of schizophrenia
(Handbook of schizophrenia / edited by H.A. Nasrallah, v. 2)
Elsevier , Sole distributors for the USA and Canada, Elsevier Science Pub. Co., 1987
大学図書館所蔵 全22件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographies and index
内容説明・目次
内容説明
This volume brings together a wealth of data on the neurochemistry and neuropharmacology of schizophrenia. It provides investigators of the etiology of schizophrenia with a basis to formulate future directions. A major portion of the book is devoted to an analysis of the dopamine neurotransmitter system in recognition of the fact that it may represent the most likely site for neurochemical abnormalities to be found in schizophrenia. Developments in the pharmacologic treatment of schizophrenia are dealt with in six authoritative reviews and the advances detailed therein may set the stage for a second generation of improved antipsychotic medications.
目次
Introduction (F.A. Henn, Stony Brook, NY, and L.E. DeLisi, Bethesda, MD). 1. A historical perspective to the chemistry and pharmacological treatment of schizophrenia (A. Carlsson, Goteborg, Sweden). 2. Two syndromes of schizophrenia as one pole of the continuum of psychosis: a conflict of the nature of the pathogen and its genomic locus (T.J. Crow, Harrow, UK). 3. Neuroanatomical localization of dopamine in the brain and spinal cord (O. Lindvall and A. Bjorklund, Lund, Sweden). 4. Pharmacology of central dopaminergic neurons (M.E. Wolf, Detroit, MI, A.Y. Deutch and R.H. Roth, New Haven, CT). 5. Central dopaminergic systems: neurophysiology and electrophysiological pharmacology (B.S. Bunney and S.R. Sesack, New Haven, CT). 6. Neuroleptic treatment of schizophrenia (J.M. Kane, Glen Oaks, NY). 7. New pharmacological treatments for schizophrenia (J.M. Cott, and N.M. Kurtz Wallingsord, CT). 8. Norepinephrine metabolism in schizophrenia (C.R. Lake, Bethesda, MD, J. Kleinman, Washington, DC, M.S. Kafka, Rockville, MD, G. Ko, Seattle, WA, S. Smith Moore, Bethesda, MD, and M. Ziegler, San Diego, CA). 9. Indoleamines and schizophrenia (S.M. Stahl, Harlow, UK, and K. Wets, London, UK). 10. The role of neuroleptics in schizophrenia (C.B. Nemeroff and G. Bissette, Durham, NC). 11. Phospholipids and prostaglandins in schizophrenia (D. Brody, A. Wolkin and J. Rotrosen, New York, NY). 12. The neuroendocrinology of schizophrenia (P. Powchik, B.M. Davis and K.L. Davis, Bronx, NY). 13. Endogenous hallucinogens and other behavioral modifying factors in schizophrenia (L.E. DeLisi and R.J. Wyatt, Bethesda, MD). 14. Pharmacological models of schizophrenia (B. Angrist, New York, NY). 15. Tardive dyskinesia and schizophrenic burnout: the possible involvement of cytotoxic free radicals (J.L. Cadet, J.B. Lohr and D.V. Jeste, Washington, DC). 16. Neurological disorders and schizophrenia (M. Trimble and D. Rogers, London, UK). 17. Genetic aspects of the biology of schizophrenia (L.R. Goldin, L.E. DeLisi, and E.S. Gershon, Bethesda, MD). 18. Conclusion (F.A. Henn, Stony Brook, NY and L.E. DeLisi, Bethesda, MD). Subject index.
「Nielsen BookData」 より